Biocon’s FY20 Growth Will Be Driven By Twin Drug Launches, Says CFO Siddharth Mittal
An employee in protective clothing takes a sample is reflected in equipment inside the research and development center at the Biocon Ltd. campus in Bengaluru, India. (Photographer: Dhiraj Singh/Bloomberg)

Biocon’s FY20 Growth Will Be Driven By Twin Drug Launches, Says CFO Siddharth Mittal

The launch of Trastusumab and Glargine in U.S. and European markets would drive Biocon Ltd.’s growth for financial year 2019-20, according to the drugmaker’s Chief Financial Officer and President S...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.